PHILADELPHIA, June 03, 2024--Jemperli trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced dMMR rectal cancer
(Bloomberg) -- GSK Plc shares plunged in the wake of a court ruling that the UK drugmaker, alongside others including Sanofi, must face trials over whether the former heartburn treatment Zantac causes cancer. Most Read from BloombergKey Engines of US Consumer Spending Are Losing Steam All at OnceGameStop Shares Surge as Gill’s Reddit Return Shows Huge BetMnuchin Chases Wall Street Glory With His War Chest of Foreign MoneyHomebuyers Are Starting to Revolt Over Steep Prices Across USAMLO Protege S
GSK has hit back against a US ruling that found it could be sued over the potential cancer-causing properties of its heartburn drug Zantac.